UNCY
NASDAQ · Biotechnology
Unicycive Therapeutics Inc
$4.64
-0.06 (-1.17%)
UNCY News2 articles
Unicycive Therapeutics Plunges After FDA Issues Second CRL on Kidney Drug
Unicycive Therapeutics shares plunged nearly 48% in premarket trading Tuesday after the FDA issued a second complete response letter for its kidney disease drug, oxylanthanum carbonate, due to third-party manufacturing issues.
FDA Decisions Loom for ACHV and UNCY Amid Manufacturing Hurdles
ACHV dropped 9.5% as its FDA deadline passed with a manufacturing-related rejection expected; UNCY fell 2.8% ahead of a June 29 decision. Both stocks face third-party manufacturing issues.